Pruritus Therapeutics Market

Global Pruritus Therapeutics Market Size (2024 to 2029)

The pruritus therapeutics market size was valued at USD 10.27 billion in 2024 and is expected to reach USD 12.04 billion by 2029. The market size is projected to grow at a CAGR of 3.23% during the forecast period 2024 to 2029.

In medical terms, itchy skin is also known as Pruritis. Pruritis refers to the sensation or feeling on the skin that the person wants to scratch the skin. This can be irritating or painful. Pruritis can be localized to one area of the human body and spread throughout the whole body. Pruritis can be underlying conditions such as dry skin, pregnancy, reaction to medication, or allergic reaction. Pruritis can turn into a chronic condition. If pruritis last for more than 6 weeks then it can be considered as chronic pruritis. Pruritis may come with Inflamed skin, Scratch marks, Bumps, spots or blisters, Dry, cracked skin, Leathery or scaly patches. There are different types of pruritis such as Brachioradial pruritis, nocturnal pruritis, pruritus ani, senile pruritis. Dry or cracked skin, scratch marks (excoriations), a thick, leathery patch of skin (lichenification), localized pain at the place of your itchy skin, and more are all signs of pruritis. The skin bleeds and rips open, Broken skin has a scaly or crusty texture, leaks a yellow to white fluid, and doesn't mend. Pruritis can be diagnosed by allergy tests, blood tests, imaging tests, and skin biopsy. The treatment of pruritis may involve using cream, medication, using nonmedical therapies to relieve itching.

Global Pruritus Therapeutics Market Drivers:

The increase in the prevalence of skin disorders such as dermatitis, urticaria, psoriasis, and allergic diseases. This increases the demand for the pruritis therapeutics market. For instance, as per Medscape, about 20% of adults get pruritus. It is found in about 25% of jaundice patients and 50% of those on renal dialysis. In between 10% and 50% of patients who seek medical care for pruritus, a systemic condition is reported as the underlying cause. According to the IJCM article, 20% of Indians would have skin conditions in 2020. In the study population, two-thirds of skin illnesses were caused by infections and eczema. Additionally, according to the Life (Basel) Journal, among Swedish children, the prevalence of atopic dermatitis was 34% in studies that were included in 2021. As pruritus is a side effect of various skin illnesses, the high prevalence of atopic dermatitis or eczema is predicted to increase demand for pruritus therapies.

The increase in research and development in the healthcare sector drives the pruritis therapeutics market growth. Additionally, the key market players are contributing and investing more in the skin care industry. The increase in awareness regarding the skin disorders such as pruritis helps to boost the market.

The neurological system of the body and the external environment may be linked to the underlying causes of pruritus. Numerous skin diseases are now more common among the world's population as a result of the increasing incidence of extreme weather. For instance, one of the most frequent causes of pruritus is exposure to the sun's UV radiation. Ozone depletion and an increase in UV radiation hitting the planet as a result of climate change have raised the occurrence of certain skin disorders that cause pruritus. Similar to how climate change has altered the environment, pruritus triggers have increased. Additionally, the number of people who suffer from pruritus is rising due to the expanding use of chemicals in personal care and cosmetics.

The increase in new product launches to treat skin care products. This is due to an increase in research and development to cure skin disorders such as pruritis. For instance, Dupixent® (sarilumab) was approved by FDA as the first and only treatment indicated for prurigo nodularis. Additionally, the increase in the prevalence of new skin diseases is due to an increase in air pollution and environmental changes. This increases the demand for skin-related disorder therapeutics and hence leads to driving the pruritis market over the forecasting period.

Global Pruritus Therapeutics Market Restraints:

The lack of knowledge regarding skin-related diseases such as pruritis, etc hinders the market growth. The lack of understanding of disease and its treatment by patients and healthcare professionals hinders market growth. The unfavourable reimbursement policies regarding pruritis treatment led to a decrease the market growth. The growth of the pruritis market is hindered by the already launched branded product patent expiry. This will lead to an increase in generic products. Additionally, the availability of numerous treatment options is the restraining factor. These are the restraining factors of the pruritis therapeutic market.

Impact of COVID-19 on the Pruritus Therapeutics Market:

The global COVID-19 pandemic had a significant impact on businesses worldwide, disrupting their operations across various industries. To control the rapid spread of the disease, numerous countries implemented lockdown measures, resulting in the temporary closure of manufacturing facilities and a halt in production. The healthcare industry, in particular, encountered significant challenges as the outbreak caused widespread confusion and misinformation, placing immense pressure on hospitals and healthcare systems worldwide.

Numerous healthcare facilities are greatly impacted by Covid-19. The market for pruritis therapeutics market initially suffered because of the pandemic. Covid-19 led to pandemic and lockdown restrictions. The lockdown in numerous countries has impacted the financial status of the market. Due to travel restrictions, there was a disruption of supply chain management. However, Urticaria has been one of the most prevalent skin symptoms observed in Covid-19 patients. For instance, according to the IJCED study, treating skin diseases like urticaria, a common dermatological problem, while under the influence of COVID-19 presented special hurdles for all medical practitioners, including dermatologists. Hence Covid-19 impacted the pruritis therapeutics market moderately.

Report Coverage:

This research report on the Pruritus Therapeutics Market has been segmented and sub-segmented based on the product type, disease type, distribution channel, and region.

Global Pruritus Therapeutics Market- By Product Type:

• Corticosteroid
• Antihistamine
• Local Anesthetic
• Immunosuppressant
• Other Product Types

Among these, the corticosteroids segment dominates the market. The corticosteroids segment is anticipated to dominate the market over the forecasting period. This is due to the increase in the prevalence of pruritis across the world. Corticosteroids are used as first-line treatment to treat atopic dermatitis or psoriasis. The increase in topical corticosteroid sales over the counter is anticipated to be the main driving factor in the segmental growth in the forecasting period. The increase in geriatric population also drives the pruritis therapeutics market. The elderly population is more prone to skin diseases hence increasing the demand for corticosteroids.

Global Pruritus Therapeutics Market- By Disease type:

• Atopic Dermatitis
• Allergic Contact Dermatitis
• Urticaria
• Others

Among these, Atopic dermatitis dominates the market. Atopic dermatitis is anticipated to dominate the market in the forecasting period. This is due to an increase in the prevalence of atopic dermatitis patients. For instance, the International Eczema Council estimates that 223 million individuals will have atopic dermatitis worldwide in 2022 (GBD 2022), of which 43 million will be children under the age of five. This increases the demand for topical corticosteroids and calcineurin inhibitors (TCI) to treat skin disorders increasing the demand for the pruritis therapeutic market. Additionally, the advantages of corticosteroid to treat the disease increases the market growth.

Global Pruritus Therapeutics Market - By Distribution Channel:

• Hospital Pharmacies
• Drug stores & Retail Pharmacies
• Online providers

Among these, drug stores and retail pharmacies dominate the pruritis therapeutics market. Drug stores & retail pharmacies are anticipated to dominate the market over the forecasting period. This is due to an increase in sales of topical corticosteroids to treat skin disorders. The increase in the presence of pharmacies drives the market growth. Additionally, as these non-prescribed drugs are easily accessible to the patients led to market growth. The online providers segment is anticipated to grow at the fastest CAGR rate. This is due to an increase in the use of smartphones, internet users, and easy access to these applications.

Global Pruritus Therapeutics Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Regionally, North America dominates the Pruritus Therapeutics Market. The North American region is anticipated to show its dominance over the forecasting period. This is due to the increase in the prevalence of skin disorders in the region. Additionally, due to an increase in approvals of treatment from regulatory authorities. For instance, in March 2021, U.S. FDA granted priority review for a new drug application for KORSUVA solution for injection for treatment for moderate-to-severe pruritis in hemodialysis patients. The increase in advancement in technology leads to increase market growth. Additionally, increase in awareness among patients regarding pruritis. These are the factors that influence regional growth.

The European segment is the second largest segment in the pruritis therapeutics market. This is due to advancements in technology and an increase in product approvals by regulatory authorities. Additionally due to increase in collaborations among key players also helps to boost the market growth. For instance, MC2 Therapeutics granted Almirall S.A. exclusive European rights to commercialize WYNZORA Cream for the treatment of plaque psoriasis, a common cause of psoriasis itching (pruritus) in adults, on February 20, 2021, according to a statement from the commercial-stage pharmaceutical company and global biopharmaceutical company Almirall S.A.

The Asia Pacific region is anticipated to expand at the fastest CAGR during the forecasting period. This is due to an increase in research and development and an increase in investment in the healthcare sector. Additionally, the increase in sales and demand for topical corticosteroids for the treatment related to skin disorders.

Key Market Players:

Some market players in the Pruritus Therapeutics Market are Pfizer, Cipla, Amgen Inc., Sanofi, Eli, Lily, and Company, Novartis AG, Cara Therapeutics, EPI Health LLC, Galderma Laboratories, AbbVie Inc., Astellas Pharma Inc.

Recent Happenings in this Market:

• In Sept 2022, Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica.
• In May 2022, Kapruvia has been approved by the European Commission for the treatment of moderate-to-severe pruritis in hemodialysis patients.